Clinical Trial

Simultaneous T2-FLAIR and T1 Brain MRI With ENRAGED FLAIR in Multiple Sclerosis

Study acronym: ENRAGED FLAIR
Completed
View on ClinicalTrials.gov →
Summary
This study will evaluate a new brain MRI technique called ENRAGED FLAIR in patients with multiple sclerosis. MRI is central in the diagnosis and follow-up of multiple sclerosis because it can show inflammatory lesions in the brain. A standard MS brain MRI examination usually includes T2-FLAIR images, which are used to detect and assess MS lesions, and T1-weighted images, which provide anatomical information and help with interpretation of lesion location. These image types are usually acquired as separate scans. ENRAGED FLAIR is designed to acquire both T2-FLAIR and T1-weighted images during the same MRI sequence. The purpose of this study is to compare ENRAGED FLAIR with standard clinical MRI in patients with multiple sclerosis. Adult patients with multiple sclerosis who are already scheduled for a clinical brain MRI may be asked to participate. Participants will undergo one additional MRI sequence during the same visit. No extra contrast agent will be given, and no extra visit is required. The additional scan is expected to increase the examination time by about 5 to 10 minutes. The study will assess whether ENRAGED FLAIR provides image quality and MS lesion visualization comparable to standard MRI. If successful, this technique may help shorten future MRI examinations for patients with multiple sclerosis while preserving clinically useful image information.
Protocol Amendment History 4 changes
critical Completed without a posted recruiting period 2026-08-14
notable Enrollment increased: 10 -> 11 participants 2026-08-14
notable Primary completion moved earlier: 2026-09-10 -> 2026-08-11 2026-08-14
minor Completion moved earlier: 2027-12-31 -> 2026-08-11 2026-08-14
Trial Details
NCT Number NCT07687693
Lead Sponsor Region Stockholm
Conditions Multiple Sclerosis
Enrollment 11 participants
Start Date 2026-08-10
Primary Completion 2026-08-11 (estimated)
Study Completion 2026-08-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-13